Similarly, BMS-986256 (Afimetoran), a mixed TLR7 and TLR8 antagonist, is currently under evaluation for efficacy and safety in SLE patients (NCT04895696) after a clinical study on pharmacokinetics in healthy male participants (NCT04269356). The gene discussed is TLR8; the disease is systemic lupus erythematosus.